HER2 / ErbB2 Recombinant Rabbit Monoclonal Antibody (IRS034)

UNIPROT #

P04626

PROTEIN NAME

HER2 / ErbB2

SYNONYMS

erb b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog antibody;C erb B2/neu protein antibody;CD340 antibody;CD340 antigen antibody;Cerb B2/neu protein antibody;CerbB2 antibody;Erb b2 receptor tyrosine kinase 2 antibody;ErbB-2 proto-oncogene antibody;ERBB2 antibody;ERBB2_HUMAN antibody;HER 2 antibody;HER 2/NEU antibody;HER2 antibody;Herstatin antibody;Human epidermal growth factor receptor 2 antibody;Metastatic lymph node gene 19 protein antibody;MLN 19 antibody;MLN19 antibody;NEU antibody;NEU proto oncogene antibody;Neuro/glioblastoma derived oncogene homolog antibody;Neuroblastoma/glioblastoma derived oncogene homolog antibody;NGL antibody;p185erbB2 antibody;Proto-oncogene c-ErbB-2 antibody;Proto-oncogene Neu antibody;Receptor tyrosine-protein kinase erbB-2 antibody;TKR1 antibody;Tyrosine kinase type cell surface receptor HER2 antibody;Tyrosine kinase-type cell surface receptor HER2 antibody;V erb b2 avian erythroblastic leukemia viral oncogene homolog 2 (neuro/glioblastoma derived oncogene homolog) antibody;V erb b2 avian erythroblastic leukemia viral oncogene homolog 2 antibody;V erb b2 avian erythroblastic leukemia viral oncoprotein 2 antibody;V erb b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian) antibody;V erb b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog antibody;Verb b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian) antibody

SUBCELLULAR LOCATION

Cell membrane, Nucleus, Cytoplasm.

FUNCTION

HER-2 (also called HER-2/neu, c-erbB2, ERBB2 or neu) is a transmembrane receptor tyrosine kinase. HER-2 is a proto-oncogene, i.e. its activation causes malignant transformation and increases the malignant potential (cell proliferation, invasiveness etc.) of the cells. Amplification of HER-2 gene invariably leads to over-expression of its protein product. The magnitude of over- expression is usually 10-100 folds or even more. Over-expressed HER-2 protein disturbs the HER-receptor family signalling networks, i.e. signalling mediated via EGFR receptor, HER-3 and HER-4. In tumours, HER-2 is over-expressed in 15-25% of primary breast cancers. Metastases usually have the same amplification status as the primary tumours. HER-2 amplification and over-expression are typical features of hormone receptor negative, rapidly growing histologic grade 2-3 tumours. Of the histologic types, Paget’s disease is almost invariably HER-2 positive, whereas only a small minority of lobular and tubular carcinomas shows HER-2 amplification. HER-2 amplification and over-expression can also be found in intestinal type gastric and gastroesophageal carcinomas, ovarian carcinomas, high grade endometrial carcinomas and some salivary duct tumours. Low-level copy number increases have been found also in rare cases of lung tumours. Because of its central importance in breast cancer therapy selection, standardization of HER-2 IHC assays and slide interpretation are of outmost clinical and economical importance.